107 related articles for article (PubMed ID: 17637501)
1. Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b.
Muñoz R; Arias Y; Ferreras JM; Rojo MA; Gayoso MJ; Nocito M; Benitez J; Jiménez P; Bernabéu C; Girbés T
Cancer Lett; 2007 Oct; 256(1):73-80. PubMed ID: 17637501
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of an ebulin l-anti-human CD105 immunotoxin on mouse fibroblasts (L929) and rat myoblasts (L6E9) cells expressing human CD105.
Benítez J; Ferreras JM; Muñoz R; Arias Y; Iglesias R; Córdoba-Díaz M; del Villar R; Girbés T
Med Chem; 2005 Jan; 1(1):65-70. PubMed ID: 16789887
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.
Muñoz R; Arias Y; Ferreras JM; Jiménez P; Langa C; Rojo MA; Gayoso MJ; Córdoba-Díaz D; Bernabéu C; Girbés T
Cancer Immunol Immunother; 2013 Mar; 62(3):541-51. PubMed ID: 23076642
[TBL] [Abstract][Full Text] [Related]
4. Anti-Human Endoglin (hCD105) Immunotoxin-Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1.
Barriuso B; Antolín P; Arias FJ; Girotti A; Jiménez P; Cordoba-Diaz M; Cordoba-Diaz D; Girbés T
Toxins (Basel); 2016 Jun; 8(6):. PubMed ID: 27294959
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
6. Transient injury-dependent up-regulation of CD105 and its specific targeting with an anti-vascular anti-mouse endoglin-nigrin b immunotoxin.
Muñoz R; Arias Y; Ferreras JM; Jiménez P; Rojo MÁ; Bernabéu C; Córdoba-Díaz D; Girbés T
Med Chem; 2012 Nov; 8(6):996-1002. PubMed ID: 22779758
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin b.
Muñoz R; Arias Y; Ferreras JM; Jiménez P; Rojo MA; Girbés T
Cancer Lett; 2001 Jun; 167(2):163-9. PubMed ID: 11369137
[TBL] [Abstract][Full Text] [Related]
8. Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l.
Citores L; Ferreras JM; Muñoz R; Benítez J; Jiménez P; Girbés T
Cancer Lett; 2002 Oct; 184(1):29-35. PubMed ID: 12104045
[TBL] [Abstract][Full Text] [Related]
9. Polynucleotide: adenosine glycosidase activity of immunotoxins containing ribosome-inactivating proteins.
Barbieri L; Bolognesi A; Valbonesi P; Polito L; Olivieri F; Stirpe F
J Drug Target; 2000; 8(5):281-8. PubMed ID: 11328656
[TBL] [Abstract][Full Text] [Related]
10. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
11. Isolation and partial characterization of nigrin b, a non-toxic novel type 2 ribosome-inactivating protein from the bark of Sambucus nigra L.
Girbés T; Citores L; Ferreras JM; Rojo MA; Iglesias R; Muñoz R; Arias FJ; Calonge M; García JR; Méndez E
Plant Mol Biol; 1993 Sep; 22(6):1181-6. PubMed ID: 8400135
[TBL] [Abstract][Full Text] [Related]
12. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
Polito L; Bolognesi A; Tazzari PL; Farini V; Lubelli C; Zinzani PL; Ricci F; Stirpe F
Leukemia; 2004 Jul; 18(7):1215-22. PubMed ID: 15103391
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line.
Battelli MG; Polito L; Bolognesi A; Lafleur L; Fradet Y; Stirpe F
Int J Cancer; 1996 Feb; 65(4):485-90. PubMed ID: 8621232
[TBL] [Abstract][Full Text] [Related]
14. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.
Fonsatti E; Nicolay HJ; Altomonte M; Covre A; Maio M
Cardiovasc Res; 2010 Apr; 86(1):12-9. PubMed ID: 19812043
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Falini B; Stirpe F
Int J Cancer; 1996 Nov; 68(3):349-55. PubMed ID: 8903477
[TBL] [Abstract][Full Text] [Related]
16. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
17. Specific dose-dependent damage of Lieberkühn crypts promoted by large doses of type 2 ribosome-inactivating protein nigrin b intravenous injection to mice.
Gayoso MJ; Muñoz R; Arias Y; Villar R; Rojo MA; Jiménez P; Ferreras JM; Aranguez I; Girbés T
Toxicol Appl Pharmacol; 2005 Sep; 207(2):138-46. PubMed ID: 16102565
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
[TBL] [Abstract][Full Text] [Related]
19. The effect of ribosome-inactivating proteins on the ribosome from the hyperthermophilic archaeon Sulfolobus solfataricus.
Raimo G; Arcucci A; Barbieri L; Valbonesi P; Masullo M; Stirpe F; Bocchini V
Biochem Mol Biol Int; 1998 Apr; 44(4):665-72. PubMed ID: 9584980
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
